Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | ME3 | Q16798 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816065 | 0.86 | GFER (0.44) | GFERCASP6ME3GAALMNA | |
| SCHEMBL3633174 | 0.86 | GPR119 (0.50) | ME3GAALMNAJAK2HDAC1 | |
| SCHEMBL3637765 | 0.85 | GFER (0.43) | GFERCASP6ME3GAALMNA | |
| SCHEMBL13724599 | 0.82 | GFER (0.51) | GFERCASP6ME3GAAF10 | |
| SCHEMBL3666064 | 0.81 | KMT2A (0.46) | LMNAMAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL21418385 | 0.77 | GFER (0.60) | GFERCASP6ME3GAALMNA | |
| SCHEMBL16611364 | 0.77 | MAPT (0.66) | GFERCASP6GAALMNAMAPT | |
| SCHEMBL30957002 | 0.76 | MGLL (0.58) | GFERCASP6GAALMNAMAPT | |
| SCHEMBL77188 | 0.76 | GFER (0.53) | GFERCASP6GAALMNAMAPT | |
| SCHEMBL3570102 | 0.76 | NOTUM (0.57) | GFERCASP6ME3GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | VIA PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GFER 1433/4885CASP6 3996/4885ME3 917/4885 |
| US-20090170864-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GFER 1433/4885CASP6 3996/4885ME3 917/4885 |
| US-20090099201-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GFER 1433/4885CASP6 3996/4885ME3 917/4885 |
| US-20090105273-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | GFER 1433/4885CASP6 3996/4885ME3 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.